The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials.
BACKGROUND
Functional impairment is associated with major depressive disorder (MDD), and patients with MDD often present with somatic symptoms.


OBJECTIVE
To examine the relationships between improved global functioning and core depressive symptoms as well as painful and nonpainful somatic symptoms in patients with MDD.


METHODS
This post hoc analysis of 2 identical trials compared the efficacy of duloxetine with that of paroxetine or placebo as treatment of MDD. In the trials, patients with DSM-IV-defined MDD received duloxetine 80 mg/day (N = 188), duloxetine 120 mg/day (N = 196), paroxetine 20 mg/day (N = 183), or placebo (N = 192) for 8 weeks. The Sheehan Disability Scale (SDS), Maier subscale of the 17-item Hamilton Rating Scale for Depression, 21-item Somatic Symptom Inventory, and Visual Analog Scale for overall pain were used to measure functional impairment, core symptoms of depression, and nonpainful and painful somatic symptoms, respectively. Baseline-to-endpoint mean changes in SDS total and subdomains were measured using analysis of variance with last-observation-carried-forward Pearson partial correlations, and path analysis was used to assess the significance of associations and relative contributions of improvement in global functional impairment, depression, and somatic symptoms. The trials were conducted from November 2000 to July 2002.


RESULTS
The difference between antidepressant treatment and placebo in SDS total and subdomains was significant (p < .001). At baseline and in change from baseline to endpoint, associations between global functional impairment and core depressive and somatic symptoms were all significant (p < .05). Path analysis demonstrated improvement of functional impairment attributed to treatment effect as 37.0% (core depressive symptoms), 13.0% (nonpainful somatic symptoms), and 11.0% (painful somatic symptoms).


CONCLUSIONS
In patients with MDD, over a third of functional improvement associated with antidepressant therapy was mediated through improvement in core depressive symptoms. In addition, a significant proportion of functional improvement, although to a lesser degree, was associated with the treatment of both nonpainful and painful somatic symptoms.
Wise
Thomas N
TN
Johns Hopkins University School of Medicine, Baltimore, Md, USA. Thomas.Wise@inova.org
Meyers
Adam L
AL
Desaiah
Durisala
D
Mallinckrodt
Craig H
CH
Robinson
Michael J
MJ
Kajdasz
Daniel K
DK
Eur Psychiatry. 2006 Sep;21(6):367-78
16697153
Pain Med. 2007 Sep;8 Suppl 2:S75-82
17714118
Psychosom Med. 2004 Jan-Feb;66(1):17-22
14747633
J Clin Psychiatry. 2004;65 Suppl 12:5-9
15315471
Arch Intern Med. 2003 Nov 10;163(20):2433-45
14609780
Am J Psychiatry. 2004 Oct;161(10):1877-84
15465986
Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70
15589385
Arch Gen Psychiatry. 1992 Feb;49(2):91-100
1550468
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
9881538
Anesth Analg. 1998 Jan;86(1):102-6
9428860
J Affect Disord. 1998 Sep;50(2-3):97-108
9858069
J Clin Psychiatry. 1998 Nov;59(11):608-19
9862607
Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45
10767867
N Engl J Med. 1999 Oct 28;341(18):1329-35
10536124
Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:89-95
8923116
Br J Psychiatry Suppl. 1996 Jun;(30):101-8
8864155
J Clin Psychiatry. 2004 Apr;65(4):521-30
15119915
Int J Psychiatry Med. 1997;27(2):93-105
9565717
J Affect Disord. 2006 Jun;92(2-3):185-93
16516977
Prim Care Companion J Clin Psychiatry. 2005;7(4):167-76
16163400
Arch Fam Med. 1994 Sep;3(9):774-9
7987511
JAMA. 2003 Jun 18;289(23):3095-105
12813115